November 8, 2018 – Flagship’s precision medicine solutions and cTA® platform are featured in a recent GEN article, Precision Biomarkers and Medicines Go Global, summarizing highlights from the recent Clinical Biomarkers and World CDx conference in Boston.
Dr. Joseph Krueger, Flagship Chief Science Officer, presented Flagship’s approach at the conference. Flagship’s cTA platform can help drug developers solve the key problems of variability, lack of precision, and insufficient clarity between test results and clinical outcome.
“By combining traditional IHC methods and stains with digital pathology approaches, our cTA platform can provide more precise data that can better predict contextual relationships between biomarker expression and treatment outcomes,” says Dr. Krueger.
For more detailed information about Flagship’s solutions, download Flagship’s white paper: Using Artificial Intelligence to Determine Patient Response to Immunotherapy.
Contact Flagship today to learn how we improve confidence in predicting contextual relationships between biomarker expression and treatment outcomes.